Inhaled Nitric Oxide and Neuroprotection in Preterm Infants

Clinics in Perinatology

Volumn 35, Issue 4, 2008, Pages 793-807

  Marks, Jeremy D ^a   Schreiber, Michael D ^b  

^a The College Committees on Cell Physiology and Molecular Medicine   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Bayley; Chronic lung disease; Intraventricular hemorrhage; Neurodevelopment; Periventricular leukomalacia

Indexed keywords

ALPHA TOCOPHEROL; CORTICOSTEROID; DEXAMETHASONE; INDOMETACIN; NITRIC OXIDE; PHENOBARBITAL; PLACEBO;

ARTIFICIAL VENTILATION; BRAIN HEMORRHAGE; CHRONIC LUNG DISEASE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG MECHANISM; DRUG SAFETY; ENCEPHALOMALACIA; HUMAN; INHALATION; NEUROPROTECTION; NONHUMAN; PREMATURITY; PRIORITY JOURNAL; RATING SCALE; RESPIRATORY FAILURE; REVIEW; RISK FACTOR;

ADMINISTRATION, INHALATION; CENTRAL NERVOUS SYSTEM DISEASES; HEART; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; LUNG; NERVOUS SYSTEM; NEUROPROTECTIVE AGENTS; NITRIC OXIDE;

EID: 56249088644     PISSN: 00955108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clp.2008.07.015     Document Type: Review

References (91)

1. Doyle L.W. Neonatal intensive care at borderline viability-is it worth it?. Early Hum Dev 80 2 (2004) 103-113
2. Wood N.S., Costeloe K., Gibson A.T., et al. The EPICure study: associations and antecedents of neurological and developmental disability at 30 months of age following extremely preterm birth. Arch Dis Child Fetal Neonatal Ed 90 2 (2005) F134-F140
3. Wood N.S., Marlow N., Costeloe K., et al. Neurologic and developmental disability after extremely preterm birth. N Engl J Med 343 6 (2000) 378-384
4. Anderson P.J., and Doyle L.W. Cognitive and educational deficits in children born extremely preterm. Semin Perinatol 32 1 (2008) 51-58
5. Aylward G.P. Neurodevelopmental outcomes of infants born prematurely. J Dev Behav Pediatr 26 6 (2005) 427-440
6. Hintz S.R., Kendrick D.E., Vohr B.R., et al. Changes in neurodevelopmental outcomes at 18 to 22 months' corrected age among infants of less than 25 weeks' gestational age born in 1993-1999. Pediatrics 115 6 (2005) 1645-1651
7. Bayley N. Bayley scales of infant development. 2nd edition (1993), Harcourt Brace, San Antonio (TX)
8. Wu Y., and Colford J.J. Chorioamnionitis as a risk factor for cerebral palsy: a meta-analysis. JAMA 290 (2000) 2677-2684
9. Ferriero D.M. Neonatal brain injury. N Engl J Med 351 19 (2004) 1985-1995
10. Neubauer A.P., Voss W., and Kattner E. Outcome of extremely low birth weight survivors at school age: the influence of perinatal parameters on neurodevelopment. Eur J Pediatr 167 1 (2008) 87-95
11. Jeng S.F., Hsu C.H., Tsao P.N., et al. Bronchopulmonary dysplasia predicts adverse developmental and clinical outcomes in very-low-birthweight infants. Dev Med Child Neurol 50 1 (2008) 51-57
12. Short E.J., Kirchner H.L., Asaad G.R., et al. Developmental sequelae in preterm infants having a diagnosis of bronchopulmonary dysplasia: analysis using a severity-based classification system. Arch Pediatr Adolesc Med 161 11 (2007) 1082-1087
13. Short E.J., Klein N.K., Lewis B.A., et al. Cognitive and academic consequences of bronchopulmonary dysplasia and very low birth weight: 8-year-old outcomes. Pediatrics 112 5 (2003) e359
14. O'Shea T.M., Kothadia J.M., Klinepeter K.L., et al. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics 104 1 Pt 1 (1999) 15-21
15. Shinwell E.S., Karplus M., Reich D., et al. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Arch Dis Child Fetal Neonatal Ed 83 3 (2000) F177-F181
16. Pillekamp F., Hermann C., Keller T., et al. Factors influencing apnea and bradycardia of prematurity - implications for neurodevelopment. Neonatology 91 3 (2007) 155-161
17. Msall M., Buck G., Rogers B., et al. Kindergarten readiness after extreme prematurity. AM J Dis Child 146 (1992) 1371-1375
18. Osborn D.A., and Hunt R.W. Postnatal thyroid hormones for respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev 1 (2007) CD005946
19. Vohr B.R., Allan W.C., Westerveld M., et al. School-age outcomes of very low birth weight infants in the indomethacin intraventricular hemorrhage prevention trial. Pediatrics 111 4 Pt 1 (2003) e340-e346
20. Roberts J.D., Fineman J.R., Morin F.C., et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. N Engl J Med 336 9 (1997) 605-610
21. The Neonatal Inhaled Nitric Oxide Study G. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med 336 9 (1997) 597-604
22. Clark R.H., Kueser T.J., Walker M.W., et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group. N Engl J Med 342 7 (2000) 469-474
23. Hogman M., Frostell C., Arnberg H., et al. Bleeding time prolongation and NO inhalation. Lancet 341 8861 (1993) 1664-1665
24. Cheung P.Y., Salas E., Etches P.C., et al. Inhaled nitric oxide and inhibition of platelet aggregation in critically ill neonates. Lancet 351 9110 (1998) 1181-1182
25. Van Meurs K.P., Rhine W.D., Asselin J.M., et al. Response of premature infants with severe respiratory failure to inhaled nitric oxide. Preemie NO Collaborative Group. Pediatr Pulmonol 24 5 (1997) 319-323
26. Kinsella J.P., Walsh W.F., Bose C.L., et al. Inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure: a randomised controlled trial. Lancet 354 9184 (1999) 1061-1065
27. Kinsella J.P., Cutter G.R., Walsh W.F., et al. Early inhaled nitric oxide therapy in premature newborns with respiratory failure. N Engl J Med 355 4 (2006) 354-364
28. Ballard R.A., Truog W.E., Cnaan A., et al. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N Engl J Med 355 4 (2006) 343-353
29. Schreiber M.D., Gin-Mestan K., Marks J.D., et al. Inhaled nitric oxide in premature infants with the respiratory distress syndrome. N Engl J Med 349 (2003) 2099-2107
30. Ballard P.L., Truog W.E., Merrill J.D., et al. Plasma biomarkers of oxidative stress: relationship to lung disease and inhaled nitric oxide therapy in premature infants. Pediatrics 121 3 (2008) 555-561
31. Subhedar N.V., Ryan S.W., and Shaw N.J. Open randomised controlled trial of inhaled nitric oxide and early dexamethasone in high risk preterm infants. Arch Dis Child Fetal Neonatal Ed 77 3 (1997) F185-F190
32. Ryan S.W., Nycyk J., and Shaw B.N. Prediction of chronic neonatal lung disease on day 4 of life. Eur J Pediatr 155 8 (1996) 668-671
33. Bennett A.J., Shaw N.J., Gregg J.E., et al. Neurodevelopmental outcome in high-risk preterm infants treated with inhaled nitric oxide. Acta Paediatr 90 5 (2001) 573-576
34. Group TF-BCNT. Early compared with delayed nitric oxide in moderately hypoxaemic neonates with respiratory failure: a randomised controlled study. Lancet 354 (1999) 1066-1071 [Erratum, Lancet 1999; 354:1826]
35. Skimming J., Bender K., Hutchinson A., et al. Nitric oxide inhalation in infants with respiratory distress syndrome. J Pediatr 130 (1997) 225-230
36. Srisuparp P., Marks J.D., Dixit R., et al. Inhaled nitric oxide improves oxygenation index without increasing intraventricular hemorrhage in premature infants with respiratory distress syndrome. J Invest Med 46 (1998) 263A
37. Srisuparp P., Heitschmidt M., and Schreiber M.D. Inhaled nitric oxide therapy in premature infants with mild to moderate respiratory distress syndrome. J Med Assoc Thai 85 Suppl 2 (2002) S469-S478
38. Garland J.S., Buck R., and Leviton A. Effect of maternal glucocorticoid exposure on risk of severe intraventricular hemorrhage in surfactant-treated preterm infants. J Pediatr 126 2 (1995) 272-279
39. Silver R.K., Vyskocil C., Solomon S.L., et al. Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered before 30 weeks' gestation. Obstetrics & Gynecology 87 5 Pt 1 (1996) 683-691
40. Crowley P., Chalmers I., and Keirse M.J. The effects of corticosteroid administration before preterm delivery: an overview of the evidence from controlled trials. [see comments]. Br J Obstet Gynaecol 97 1 (1990) 11-25
41. Donn S.M., Roloff D.W., and Goldstein G.W. Prevention of intraventricular haemorrhage in preterm infants by phenobarbitone. A controlled trial. Lancet 2 8240 (1981) 215-217
42. Crowther C., and Henderson-Smart D. Phenobarbital prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database Syst Rev (2003) Issue 3:Art. No.:CD000164
43. Bada H.S., Green R.S., Pourcyrous M., et al. Indomethacin reduces the risks of severe intraventricular hemorrhage. [see comments]. J Pediatr 115 4 (1989) 631-637
44. Ment L.R., Ehrenkranz R.A., Duncan C.C., et al. Low-dose indomethacin and prevention of intraventricular hemorrhage: a multicenter randomized trial. Pediatrics 93 4 (1994) 543-550
45. Chiswick M., Gladman G., Sinha S., et al. Vitamin E supplementation and periventricular hemorrhage in the newborn. Am J Clin Nutr 53 1 Suppl (1991) 370S-372S
46. Jarvenpaa A.L., Vlrtanen M., and Pohjavuori M. The outcome of extremely low birthweight infants. Ann Med 23 6 (1991) 699-704
47. Patel C.A., and Klein J.M. Outcome of infants with birth weights less than 1000 g with respiratory distress syndrome treated with high-frequency ventilation and surfactant replacement therapy. Arch Pediatr Adolesc Med 149 3 (1995) 317-321
48. Vohr B.R., Wright L.L., Dusick A.M., et al. Neurodevelopmental and functional outcomes of extremely low birth weight infants in the National Institute of Child Health and Human Development Neonatal Research Network, 1993-1994. Pediatrics 105 6 (2000) 1216-1226
49. Hintz S.R., and O'Shea M. Neuroimaging and Neurodevelopmental Outcomes in Preterm Infants. Semin Perinatol 32 1 (2008) 11-19
50. De Vries L., Groenendaal F., and van Haastert I. Asymmetrical myelination of the posterior limb of the internal capsule in infants with periventricular haemorrhagic infarction: an early predictor of hemiplegia. Neuropediatrics 30 (1999) 314-319
51. Nanba Y., Matsui K., and Aida N. Magnetic resonance imaging regional T1 abnormalities at term accurately predict motor outcome in preterm infants. Pediatrics 120 (2007) e10-e19
52. Sie L., Hart A., and van Hof J. Predictive value of neonatal MRI with respect to late MRI findings and clinical outcome. A study in infants with periventricular densities on neonatal ultrasound. Neuropediatrics 36 (2005) 78-89
53. Mestan K.L., Marks J.D., Hecox K., et al. Neurodevelopmental outcomes of premature infants treated with inhaled nitric oxide. N Engl J Med 353 1 (2005) 23-32
54. Van Meurs K.P., Wright L.L., Ehrenkranz R.A., et al. Inhaled nitric oxide for premature infants with severe respiratory failure. N Engl J Med 353 1 (2005) 13-22
55. Hintz S.R., Van Meurs K., Perritt R., et al. Neurodevelopmental outcomes of premature infants with severe respiratory failure enrolled in a randomized controlled trial of inhaled nitric oxide. J Pediatr 151 1 (2007) 16-22
56. Field D., Elbourne D., Truesdale A., et al. Neonatal ventilation with inhaled nitric oxide versus ventilatory support without inhaled nitric oxide for preterm infants with severe respiratory failure: the innovo multicentre randomised controlled trial (ISRCTN 17821339). Pediatrics 115 4 (2005) 926-936
57. Tanaka Y., Hayashi T., Kitajima H., et al. Inhaled nitric oxide therapy decreases the risk of cerebral palsy in preterm infants with persistent pulmonary hypertension of the newborn. Pediatrics 119 6 (2007) 1159-1164
58. Back S.A., Han B.H., Luo N.L., et al. Selective vulnerability of late oligodendrocyte progenitors to hypoxia- ischemia. J Neurosci 22 2 (2002) 455-463
59. Drobyshevsky A., Song S.-K., Gamkrelidze G., et al. Developmental changes in diffusion anisotropy coincide with immature oligodendrocyte progression and maturation of compound action potential. J Neurosci 25 25 (2005) 5988-5997
60. McQuillen P.S., Sheldon R.A., Shatz C.J., et al. Selective vulnerability of subplate neurons after early neonatal hypoxia-ischemia. J Neurosci 23 8 (2003) 3308-3315
61. Calabrese V., Mancuso C., Calvani M., et al. Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nat Rev Neurosci 8 (1997) 766-775
62. Guix Fu I., Coma M., and Munoz F. The physiology and pathophysiology of nitric oxide in the brain. Prog Neurobiol 76 (2005) 126-152
63. Motterlini R., green C., and Foresti R. Regulation of heme oxygenase-1 by redox signals involving nitric oxide. Antioxid Redox Signal 4 (2002) 615-624
64. Mollace V., Muscoli C., Masini E., et al. Modulation of prostaglandin biosynthesis by nitric oxide and nitric oxide donors. Pharmacol Rev 57 (2005) 217-252
65. Viscardi R., Muhumuza C., and Rodriquez A. Inflammatory markers in intrauterine and fetal blood and cerebrospinal fluid compartments are associated with adverse pulmonary and neurologic outcomes in preterm infants. Pediatr Res 55 (2004) 1009-1017
66. Haynes R., Baud O., and Li J. Oxidative and nitrative injury in periventricular leukomalacia. Brain Pathol 15 (2005) 225-233
67. Aaltonen M., Soukka H., and Halkola R. Inhaled nitric oxide treatment inhibits neuronal injury after meconium aspiration in piglets. Early Hum Dev 83 (2007) 77-85
68. Dawson V.L., Dawson T.M., London E.D., et al. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. PNAS 88 14 (1991) 6368-6371 91296822
69. Gunasekar P.G., Kanthasamy A.G., Borowitz J.L., et al. NMDA receptor activation produces concurrent generation of nitric oxide and reactive oxygen species: implication for cell death. J Neurochem 65 5 (1995) 2016-2021
70. Strijbos P.J. Nitric oxide in cerebral ischemic neurodegeneration and excitotoxicity. Crit Rev Neurobiol 12 3 (1998) 223-243
71. Lipton S.A. Neuronal protection and destruction by NO. Cell Death Differ 6 10 (1999) 943-951
72. Brown G.C., and Borutaite V. Nitric oxide, mitochondria, and cell death. IUBMB Life. 52 3-5 (2001) 189-195
73. Goldberg M.P., Weiss J.H., Pham P.C., et al. N-methyl-D-aspartate receptors mediate hypoxic neuronal injury in cortical culture. J Pharmacol Exp Ther 243 2 (1987) 784-791
74. Choi D.W. Glutamate neurotoxicity and disease of the central nervous system. Neuron 1 (1988) 623-634 39
75. MacDermott A.B., Mayer M.L., Westbrook G.L., et al. NMDA-receptor activation increases cytoplasmic calcium concentration in cultured spinal cord neurones. [published erratum appears in Nature 1986 Jun 26-Jul 2;321(6073):888]. Nature 321 6069 (1986) 519-522
76. Regehr W.G., and Tank D.W. Postsynaptic NMDA receptor-mediated calcium accumulation in hippocampal CA1 pyramidal cell dendrites. Nature 345 6278 (1990) 807-810
77. Hartley D.M., Kurth M.C., Bjerkness L., et al. Glutamate receptor-induced 45Ca2+ accumulation in cortical cell culture correlates with subsequent neuronal degeneration. J Neurosci 13 5 (1993) 1993-2000 93240223
78. Sattler R., Charlton M.P., Hafner M., et al. Distinct influx pathways, not calcium load, determine neuronal vulnerability to calcium neurotoxicity. J Neurochem 71 6 (1998) 2349-2364
79. Sattler R., Xiong Z., Lu W.Y., et al. Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science 284 5421 (1999) 1845-1848 99294869
80. Schulz J.B., Matthews R.T., Klockgether T., et al. The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases. Mol Cell Biochem 174 1-2 (1997) 193-197
81. Misko T.P., Highkin M.K., Veenhuizen A.W., et al. Characterization of the cytoprotective action of peroxynitrite decomposition catalysts. J Biolumin Chemilumin 273 25 (1998) 15646-15653
82. Schechter A.N., and Gladwin M.T. Hemoglobin and the paracrine and endocrine functions of nitric oxide. N Engl J Med 348 15 (2003) 1483-1485
83. Gladwin M.T., Lancaster Jr. J.R., Freeman B.A., et al. Nitric oxide's reactions with hemoglobin: a view through the SNO-storm. Nat Med 9 5 (2003) 496-500
84. McMahon T., Moon R., and Luschinger B. Nitric oxide in the human respiratory cycle. Nat Med 8 (2002) 711-717
85. Joshi M., Ferguson T.J., and Han T. Nitric oxide is consumed, rather than conserved, by reaction with oxyhemoglobin under physiological conditions. PNAS 99 (2002) 10341-10346
86. 2/NO-linked allosteric function. J Biolumin Chemilumin 277 (2002) 27818-27828
87. Dalkara T., Yoshida T., Irikura K., et al. Dual role of nitric oxide in focal cerebral ischemia. Neuropharmacology 33 11 (1994) 1447-1452
88. Huang Z., Huang P.L., Panahian N., et al. Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. Science 265 5180 (1994) 1883-1885
89. Takemoto M., Sun J., Hiroki J., et al. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 106 (2002) 57-62
90. Wolfrum S., Dendorfer A., Rikitake Y., et al. Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arterioscler Thromb Vasc Biol 24 (2004) 1842-1847
91. Rikitake Y., Kim H., Huang Z., et al. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke 36 (2005) 2251-7